Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423908 | 0.91 | MAPK8 (0.32) | MAPK8JAK2JAK3PTK2KDM5B | |
| SCHEMBL31423988 | 0.91 | MAPK8 (0.32) | MAPK8JAK2JAK3PTK2KDM5B | |
| SCHEMBL31423976 | 0.91 | MAPK8 (0.32) | MAPK8JAK2JAK3PTK2KDM5B | |
| SCHEMBL31423901 | 0.91 | MAPK8 (0.32) | MAPK8JAK2JAK3PTK2 | |
| SCHEMBL31423920 | 0.90 | ATR (0.33) | MAPK8ATRJAK2JAK3PTK2 | |
| SCHEMBL31423925 | 0.88 | MAPK8 (0.31) | MAPK8 | |
| SCHEMBL31423914 | 0.88 | MAPK8 (0.31) | MAPK8 | |
| SCHEMBL31423981 | 0.88 | MAPK8 (0.31) | MAPK8 | |
| SCHEMBL31423962 | 0.88 | MAPK8 (0.33) | MAPK8ATRJAK2JAK3PTK2 | |
| SCHEMBL31423883 | 0.88 | MAPK8 (0.33) | MAPK8ATRJAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054386-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |